𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series

✍ Scribed by Liliana Montella; Raffaele Addeo; Giovannella Palmieri; Michele Caraglia; Gregorio Cennamo; Bruno Vincenzi; Rosario Guarrasi; Rosanna Mamone; Vincenzo Faiola; Nicola Frega; Elena Capasso; Luigi Maiorino; Davide Leopardo; Carmine Pizza; Vincenzo Montesarchio; Salvatore Del Prete

Publisher
Springer
Year
2009
Tongue
English
Weight
845 KB
Volume
65
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who

Hepatocellular carcinoma after renal tra
Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: A case series
✍ Saeian, Kia ;Franco, JosΓ© ;Komorowski, Richard A. ;Adams, Mark B. πŸ“‚ Article πŸ“… 1999 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 171 KB

The occurrence of hepatocellular carcinoma (HCC) in renal transplant recipients has typically been associated with hepatitis B or C infection. We encountered two cases of HCC in renal transplant recipients with negative hepatitis B and C markers and no underlying liver pathology, in whom immunosuppr